US FDA CTP checks itself to move forward in response to Reagan-Udall report

The US Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has published a number of milestones to expect in the near term as it continues to address issues brought up by the Reagan-Udall Foundation’s recent report.

As part of this – and potentially for the first time – the FDA CTP acknowledged the role alternatives to traditional cigarettes could play in smoking cessation and said it wanted science to inform future public awareness campaigns.

Read full article
I'm already a subscriber

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the TobaccoIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global novel nicotine market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

TobaccoIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organisation